title: [Impact of highly active antiretroviral therapy in the clinical, immunological and virological response from AIDS patients].
abstract: A longitudinal prospective study was made to evaluate the clinical, immunological and virological response of a cohort of 34 AIDS patients in Cienfuegos provinces, who had been treated with highly active antiretroviral therapy (HAART). Males comprised 67.6% of the total number and average age was 32 years. Sexual infection path was identified in 91.2% of cases. The CD4+ T counting under 200 cells defined AIDS in 79.4% of individuals. Twenty six patients suffered minor opportunistic infections (76.5%) whereas 32.4% got sick due to some major opportunistic disease prior to the therapy. After this therapy, these frequencies lowered to 20.6% and 11.8% respectively. Average CD4+ counting at the starting of HAART was 196 cell/mm3 and exceeded 400 cells in the rest of further countings. From a PVC average of 15 251 copies/mL one year after therapy, this figure reduced to 8 048 copies at 2 years. Only 10 cases required hospitalization after a HAART (29.4%). Treatment adherence reached over 80% and was correlated to immunological restoration. Survival after one year was 100% and only 2 patients died in the following 4 years. The positive impact of HAART on the frequency of opportunistic infections, immunological restoration and survival was proved.
authors: Hospital General Universitario Gustavo Alderegía Lima, Cienfuegos, Cuba. rcorcho@ucf.edu.cu
authors: Andrés
authors: A
authors: Reyes Corcho
authors: Miguel A
authors: MA
authors: Mosquera Fernández
authors: Yanelka
authors: Y
authors: Bouza Jiménez
authors: Jorge
authors: J
authors: Pérez Avila
authors: Vivian
authors: V
authors: Hernández
authors: Blas
authors: B
authors: Jam Morales
authors: Gustavo
authors: G
authors: Alvarez Amador
authors: Yadira
authors: Y
authors: Bouza Jiménez
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000453:epidemiology / Q000517:prevention & control; D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D001379:Azathioprine / Q000008:administration & dosage / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D003462:Cuba / Q000453:epidemiology; D005260:Female; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D053208:Kaplan-Meier Estimate; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D011446:Prospective Studies; D018119:Stavudine / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load; D014766:Viremia / Q000188:drug therapy* / Q000276:immunology; D016903:Drug Monitoring
chemical_list: D019380:Anti-HIV Agents; D019259:Lamivudine; D018119:Stavudine; D001379:Azathioprine